CLL Society organized a letter to the Centers of Medicare and Medicaid Services (CMS) arguing the agency use its discretion to implement certain Inflation Reduction Act (IRA) provisions so as to support its patients. Several rare cancer groups and a large provider organization joined our efforts on behalf of patients with rare cancers, highlighting thst upcoming agency decisions will directly affect whether providers, including community oncology practices, rural hospitals, and specialized infusion centers can continue to deliver timely access to high-cost physician-administered therapies.
